Drug targets for Cancer: CD25

Drug Targets for Cancer: CD25 and Cancer

CD25 (IL-2Ra) is the a-subunit of the membrane-bound interleukin-2 receptor (IL-2R), which is mainly expressed by regulatory T cells. In addition, CD25 expression was also identified on natural killer cells, activated B and T cells and, some dendritic cells. Functionally, CD25 is essential for IL-2R signaling by binding the ligand interleukin-2 (IL-2). Stimulation of IL-2R promotes T-cell proliferation, differentiation, and cell survival. Regulatory T cells (Tregs) protect against autoimmunity, but in cancer, Tregs infiltrate even the earliest neoplastic lesions and undermine anti-tumor effector T cells. Treg development and homeostasis are critically dependent on interleukin-2 (IL-2), and most Tregs express high levels of CD25, the cell surface α chain of the IL-2 receptor. In tumor-bearing mice, CD25 monoclonal antibody (mAb) can be used to deplete CD25+ Tregs in vivo and enhance tumor immunity and immunotherapy;

Drug Targets for Cancer: CD25 related Products

Drug targets for cancer: CD25 research reagents

Other vital drug targets for cancer likeCD25:

Drug Targets for Cancer: CD25 Related Reference

Regulatory T cells (Tregs) protect against autoimmunity, but in cancer, Tregs infiltrate even the earliest neoplastic lesions and undermine anti-tumor effector T cells (1–4). Treg development and homeostasis are critically dependent on interleukin-2 (IL-2) (5–9), and most Tregs express high levels of CD25, the cell surface α chain of the IL-2 receptor (3). In tumor-bearing mice, CD25 monoclonal antibody (mAb) can be used to deplete CD25+ Tregs in vivo and enhance tumor immunity and immunotherapy (10–12);
Meyer A, Gruber A D, Klopfleisch R. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells[J]. Veterinary Pathology Online, 2012, 49(6): 988-997.

Drug Targets for Cancer: CD25 Related Information

Drug Targets for Cancer